Untitled Document
BIO PRODUCT LAUNCH POLICY
SYNGENTA IMPLEMENTATION PRINCIPLES

Syngenta is committed to bringing new technology to the market place to help meet the growing demand for food, feed and fuel. In doing so, Syngenta supports the BIO product launch policy which was developed by the members of BIO’s Food and Agriculture Section. We will be guided by the following principles as we commercialize new products:

  1. We will conduct market and trade assessments to identify key import markets for all of our biotech products prior to product commercialization.


  2. For each biotech product, at the time U.S. submissions are completed, we will begin to consult with the major, relevant trade and value chain stakeholders on our detailed plans for pre-commercial activities, and full scale commercialization.


  3. We will meet all necessary regulatory requirements in key exporting countries (where the seed will be commercialized) and importing countries that have functioning regulatory systems, which currently include the United States, Canada and Japan, prior to commercialization, unless determined otherwise in consultation with the value chain that a dedicated grain management system is workable for a specific product.


  4. We will make available prior to commercialization a reliable detection method or test that enables event identity in the crop.


  5. We are committed to the principles of good stewardship, which are exemplified through the responsible management of our products across their lifecycle, from research through development and commercialization to their discontinuation and withdrawal from the market.


  6. We will continue to work at the global level with the value chain to engage in efforts to harmonize science-based agriculture biotechnology regulatory approaches to achieve Global AP tolerances and synchronous authorizations.

In 2008 Syngenta does not have plans to introduce additional new traits for commercial planting in the U.S. All of our new traits will only be grown under regulated field trials as they proceed through the regulatory review process in 2008.

November 2007